Busy day at IR,... my response just received:

Following our Sept 30 NR, where we reported that BETonMACE did not meet its primary endpoint, all preliminary analysis of key secondary and exploratory endpoints, including cognitive decline in this patient population, were reported in the same manner – conference call and webcast. Any decisions on Company NRs are made at the senior management level. Both AHA and CtAD conferences had media presence and the Company took advantage of all interview opportunities when embargos were lifted.

The Nov. 18 and Dec. 6 webcast / conf. call and presentations have all the updated info as to next commercialization steps and the information has been widely shared to the general public and beyond.